Research Capsules

December 2005
Pharmaceutical Representative;Dec2005, Vol. 35 Issue 12, p13
The article features various drugs available in the U.S. as of December 2005. Glucose-lowering drug Actos may reduce cardiovascular risks in patients with type-2 diabetes when added to standard medication. Genentech Inc.'s Herceptin may significantly reduce the risk of disease recurrence in women with early-stage, operable, human epidermal growth factor receptor-2 positive breast cancer. AstraZeneca's Atacand may decrease the risk of heart attack or cardiovascular mortality in heart failure patients


Related Articles

  • Genentech's T-DMI Outdoes Herceptin Plus Chemotherapy.  // Bioworld Week;10/18/2010, Vol. 18 Issue 42, p3 

    The article reports on the results of a 137-patient Phase II study conducted by the Mayo Clinic investigators in Florida that shows that patients with HER2-positive metastatic breast cancer who were treated with trastuzumab-DM1 (T-DM1) antibody-drug with ImmunoGen Inc.'s DM1 cancer-cell fighting...

  • Genentech Caught off Guard, FDA Issues Refuse-to-File for T-DM1. Hollingsworth, Catherine // BioWorld Today;8/30/2010, Vol. 21 Issue 167, p1 

    The article focuses on a refuse-to-file letter sent by the U.S. Food and Drug Administration (FDA) to Genentech Inc. rejecting its application for an accelerated approval of its trastuzumab-DNA methyltransferase inhibitor (T-DMI). Genentech conducted a study which indicated that T-DMI reduced...

  • Tykerb, Herceptin Work Together in Breast Cancer.  // Bioworld Week;5/26/2008, Vol. 16 Issue 21, p2 

    The article reports on the Phase III trial which reveals that the combination of cancer drug Tykerb from GlaxoSmithKline PLC and Herceptin from Genentech Inc. works better in heavily pre-treated breast cancer. The study showed that the women pre-treated with the combination of Tykerb and...

  • FDA, Genentech Warn of Damaged Herceptin.  // BioWorld Today;7/14/2008, Vol. 19 Issue 135, p9 

    The article reports that the U.S. Food and Drug Administration (FDA) through its MedWatch program, circulated a "Dear Health Care Provider" letter from Genentech Inc. The letter includes a warning that the firm has increased number of complaints about vial damages of its breast cancer drug,...

  • Genentech posts updated survival data from pivotal Herceptin studies.  // PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p10 

    The article reports that Genentech Inc. has posted positive survival and cancer recurrence data of its phase III trials for Herceptin, a humanized antibody used to treat breast cancer. According to the author, the addition of Herceptin to standard adjuvant therapy has improved the survival rates...

  • Genentech: Herceptin hope for breast cancer sufferers.  // PharmaWatch: Biotechnology;Jun2005, Vol. 4 Issue 6, p5 

    The article reports on the positive outcomes of two phase III clinical trials of Herceptin from Genentech Inc. for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The company declared that the drug can lower the recurrence of early-stage HER2-positive...

  • Invitrogen's Herceptin test approved.  // Biomedical Business & Technology;Aug2008, Vol. 31 Issue 8, p28 

    The article reports that the U.S. Food and Drug Administration (FDA) has given premarket approval (PMA) to Invitrogen for its Spot-Light HER2 Classical Intrafascial Supracervical Hysterectomy (CISH) Kit to help in the assessment of breast cancer patients for whom Herceptin treatment is being...

  • Tykerb-Herceptin Combo Reduces Disease Progression. Hollingsworth, Catherine // BioWorld Today;5/19/2008, Vol. 19 Issue 97, p1 

    This article states that Tykerb, a cancer drug developed by GlaxoSmithKline PLC, worked better in heavily pre-treated breast cancer patients when paired with Genentech Incorporated's Herceptin drug based on the results of Phase III clinical trials. Women in the clinical trials survived eight...

  • T-DM1 Slows Breast Cancer, With Fewer Side Effects. Breindl, Anette // BioWorld Today;6/5/2012, Vol. 23 Issue 108, p2 

    The article reports that Genentech Inc. and ImmunoGen Inc. have presented data from the Phase III Emilia trial of T-DMI antibody drug at the plenary session of the 2012 annual meeting of the American Society of Clinical Oncology (ASCO). The trastuzumab emtansine is developed to treat locally...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics